Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform.

Chikungunya Dengue One Health RNA virus SARS-CoV-2 cell biology human infectious disease microbiology reverse genetics

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
21 Nov 2023
Historique:
medline: 23 11 2023
pubmed: 21 11 2023
entrez: 21 11 2023
Statut: epublish

Résumé

Reverse genetic systems enable the engineering of RNA virus genomes and are instrumental in studying RNA virus biology. With the recent outbreak of the coronavirus disease 2019 pandemic, already established methods were challenged by the large genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein we present an elaborated strategy for the rapid and straightforward rescue of recombinant plus-stranded RNA viruses with high sequence fidelity using the example of SARS-CoV-2. The strategy called CLEVER (CLoning-free and Exchangeable system for Virus Engineering and Rescue) is based on the intracellular recombination of transfected overlapping DNA fragments allowing the direct mutagenesis within the initial PCR-amplification step. Furthermore, by introducing a linker fragment - harboring all heterologous sequences - viral RNA can directly serve as a template for manipulating and rescuing recombinant mutant virus, without any cloning step. Overall, this strategy will facilitate recombinant SARS-CoV-2 rescue and accelerate its manipulation. Using our protocol, newly emerging variants can quickly be engineered to further elucidate their biology. To demonstrate its potential as a reverse genetics platform for plus-stranded RNA viruses, the protocol has been successfully applied for the cloning-free rescue of recombinant Chikungunya and Dengue virus.

Identifiants

pubmed: 37988285
doi: 10.7554/eLife.89035
pii: 89035
pmc: PMC10662946
doi:
pii:

Substances chimiques

RNA, Viral 0

Banques de données

SRA
['PRJNA971789']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Innosuisse - Schweizerische Agentur für Innovationsförderung
ID : #52533.1 IP-LS

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2023, Kipfer, Hauser et al.

Déclaration de conflit d'intérêts

EK, DH, ML, FO, LU, YZ, CL, MC, CM, TK No competing interests declared

Références

Emerg Microbes Infect. 2022 Dec;11(1):227-239
pubmed: 34931940
Nat Protoc. 2021 Mar;16(3):1761-1784
pubmed: 33514944
Nature. 2022 Feb;602(7896):294-299
pubmed: 34818667
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5516-21
pubmed: 10805807
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Viruses. 2022 Jan 18;14(2):
pubmed: 35215765
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
EMBO Rep. 2022 May 4;23(5):e53820
pubmed: 35239997
mBio. 2020 Sep 25;11(5):
pubmed: 32978313
J Gen Virol. 2014 Nov;95(Pt 11):2462-2467
pubmed: 25053561
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
J Biol Chem. 2021 Nov;297(5):101270
pubmed: 34695416
Nature. 2020 Apr;580(7803):E7
pubmed: 32296181
PLoS Biol. 2021 Mar 29;19(3):e3001158
pubmed: 33780434
Viruses. 2022 Nov 30;14(12):
pubmed: 36560685
J Gen Virol. 2001 Jun;82(Pt 6):1273-1281
pubmed: 11369870
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
PLoS Pathog. 2021 Jan 21;17(1):e1009233
pubmed: 33476327
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Med J Armed Forces India. 2022 Jul;78(3):333-338
pubmed: 35855702
Chembiochem. 2001 Mar 2;2(3):212-9
pubmed: 11828447
Nat Commun. 2021 Jun 8;12(1):3431
pubmed: 34103499
Cell Rep. 2021 Apr 20;35(3):109014
pubmed: 33838744
J Med Virol. 2022 Jul;94(7):3017-3031
pubmed: 35324008
Emerg Microbes Infect. 2018 Mar 21;7(1):40
pubmed: 29559627
J Virol. 2000 Nov;74(22):10600-11
pubmed: 11044104
PLoS One. 2015 Sep 25;10(9):e0138703
pubmed: 26407018
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
J Virol. 2013 Dec;87(23):12667-74
pubmed: 24049164
Int J Mol Sci. 2021 Sep 22;22(19):
pubmed: 34638527
Microbiol Spectr. 2023 Mar 6;:e0338522
pubmed: 36877070
J Biochem Biophys Methods. 2001 Oct 30;49(1-3):455-65
pubmed: 11694294
Nature. 2020 Jun;582(7813):561-565
pubmed: 32365353
Virus Res. 2006 Dec;122(1-2):119-26
pubmed: 16920216
PLoS Biol. 2021 Feb 25;19(2):e3001091
pubmed: 33630831
Antiviral Res. 2023 Feb;210:105486
pubmed: 36657881

Auteurs

Enja Tatjana Kipfer (ET)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

David Hauser (D)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Martin J Lett (MJ)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Fabian Otte (F)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Lorena Urda (L)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Yuepeng Zhang (Y)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Christopher M R Lang (CMR)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Mohamed Chami (M)

BioEM Lab, Biozentrum, University of Basel, Mattenstrasse, Basel, Switzerland.

Christian Mittelholzer (C)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Thomas Klimkait (T)

Molecular Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH